Kringle Pharma, Inc. (4884.T)
JPY 812.0
(-0.49%)
JPY 812.0
(-0.49%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.61 Billion JPY | -18.39% |
| 2022 | 3.2 Billion JPY | 21.74% |
| 2021 | 2.63 Billion JPY | 12.14% |
| 2020 | 2.35 Billion JPY | 833.12% |
| 2019 | 251.86 Million JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.84 Billion JPY | 8.63% |
| 2024 Q3 | 2.94 Billion JPY | 1.01% |
| 2024 Q2 | 2.91 Billion JPY | 2.37% |
| 2023 FY | 2.61 Billion JPY | -18.39% |
| 2023 Q1 | 3.04 Billion JPY | -5.01% |
| 2023 Q2 | 2.87 Billion JPY | -5.8% |
| 2023 Q4 | 2.61 Billion JPY | -7.62% |
| 2023 Q3 | 2.83 Billion JPY | -1.27% |
| 2022 Q4 | 3.2 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 60.259% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -116.163% |
| GNI Group Ltd. | 62.39 Billion JPY | 95.803% |
| Linical Co., Ltd. | 18.53 Billion JPY | 85.876% |
| Trans Genic Inc. | 9.81 Billion JPY | 73.309% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 53.522% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 62.301% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 54.978% |
| AnGes, Inc. | 28.89 Billion JPY | 90.937% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -201.941% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.334% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -61.787% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 48.363% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 39.799% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -7.637% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -10.335% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 62.214% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -49.513% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 48.508% |
| PeptiDream Inc. | 67.12 Billion JPY | 96.099% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -28.328% |
| Ribomic Inc. | 3.54 Billion JPY | 26.178% |
| SanBio Company Limited | 5.04 Billion JPY | 48.118% |
| Healios K.K. | 15.15 Billion JPY | 82.721% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -112.854% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 13.175% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -77.638% |
| StemRIM | 9.08 Billion JPY | 71.16% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 61.937% |
| FunPep Company Limited | 2.49 Billion JPY | -5.119% |
| Stella Pharma Corporation | 3.82 Billion JPY | 31.46% |
| TMS Co., Ltd. | 3.55 Billion JPY | 26.334% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 54.686% |
| Cuorips Inc. | 6.18 Billion JPY | 57.659% |
| K Pharma,Inc. | 3.31 Billion JPY | 20.98% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.875% |
| ReproCELL Incorporated | 9.05 Billion JPY | 71.073% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 3.56% |
| StemCell Institute Inc. | 6.54 Billion JPY | 59.978% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 62.531% |
| CellSeed Inc. | 2.46 Billion JPY | -6.2% |